Related Experiment Videos
[The cell cycle and the tumor suppressor genes]
1Department of Molecular Biology, Graduate School of Medical Science, Kyushu University, Fukuoka, Japan.
Abstract:
Cell cycle progression is controlled by cyclin-dependent kinases (CDKs) at the transition of both G1 to S and G2 to M phases. The activities of CDKs are negatively regulated by CDK inhibitors. Deregulation of CDK activity at the G1-S transition allows an aberrant progression of the cell cycle in tumor cells. Recent developments on cell cycle control have revealed a signal transducing pathway of tumor suppressor genes, p53 and pRb, concerning CDK and CDK inhibitors. CDK inhibitor p21 is a target of p53. p53 binds a promoter of the p21 gene and activates the transcription of p21. Consequently, cell cycle progression is blocked at the G1 phase through the suppression of CDK activity. pRb is a substrate of CDK. pRb functions to suppress cell cycle progression at the G1 phase associated with the E2F transcription factor. Phosphorylated pRb by CDK releases an active E2F, which promotes the expression of genes whose products may play a crucial role in controlling G1-S progression. These findings have deepened our understanding on the molecular mechanisms of tumor growth suppression.
Insights
Cell cycle control involves cyclin-dependent kinases (CDKs) and inhibitors. Tumor suppressor genes p53 and pRb regulate CDK activity, impacting cell cycle progression and tumor growth.
Area of Science:
- Molecular Biology
- Cell Biology
- Cancer Biology
Context:
- Cell cycle progression is tightly regulated by cyclin-dependent kinases (CDKs) at critical checkpoints.
- CDK activity is modulated by CDK inhibitors, crucial for preventing uncontrolled cell proliferation.
- Aberrant cell cycle progression, particularly at the G1-S transition, is a hallmark of cancer.
Purpose:
- To elucidate the roles of tumor suppressor genes p53 and pRb in regulating cell cycle control.
- To investigate the molecular mechanisms by which p53 and pRb influence CDK activity and cell cycle progression.
- To understand the signal transduction pathways involving p53, pRb, CDKs, and CDK inhibitors in the context of tumor suppression.
Summary:
- The tumor suppressor protein p53 activates the transcription of CDK inhibitor p21, which suppresses CDK activity and blocks cell cycle progression at the G1 phase.
- The retinoblastoma protein (pRb) acts as a substrate for CDK; when phosphorylated by CDK, pRb releases the E2F transcription factor.
- Active E2F promotes the expression of genes essential for G1-S phase transition, highlighting a key regulatory axis in cell cycle control.
Impact:
- These findings enhance the understanding of molecular mechanisms underlying tumor growth suppression.
- The study identifies critical regulatory nodes in cell cycle control that are frequently dysregulated in cancer.
- This knowledge provides a foundation for developing targeted cancer therapies aimed at restoring cell cycle control.